ClearOne, Inc.

The merger with Cortigent, Vivani Medical's neurostimulation unit, represents a compelling strategic transformation. ClearOne's Chairman Eric Robinson emphasized the significant unmet market need for precision neurostimulation technology, and the deal triggered a 170%+ stock surge, signaling strong investor confidence in the new direction.

The merger requires issuing 12.5 million new shares plus up to 855,000 advisor shares, resulting in Vivani holding approximately 77.98% control of the combined entity. This massive dilution raises serious concerns about existing shareholders' value and ClearOne's ability to maintain meaningful strategic influence post-merger.

ClearOne plans to raise $10–15 million concurrently with the Cortigent merger closing. Management has stated this capital raise will give the combined company a strong financial foundation to advance its neurostimulation pipeline, potentially accelerating product development and commercialization timelines.

The combination of 12.5 million new shares issued for the acquisition, up to 855,000 advisor shares, and an additional $10–15 million unit offering creates a multi-layered dilution risk. Existing shareholders face substantial ownership erosion, and the sufficiency of the capital raise for a capital-intensive medtech pipeline remains uncertain.

CLRO shares gained 79% year-to-date as of early July 2026, and the merger announcement catalyzed a dramatic single-day surge of over 170%. Retail sentiment shifted to 'extremely bullish,' reflecting renewed conviction in ClearOne's repositioned business model and its exposure to the high-growth neurostimulation market.

ClearOne stock is flagged for characteristically high price volatility, with a 52-week range spanning from $2.71 to $16.50. The extreme price swings suggest speculative trading dynamics rather than fundamental valuation support, raising concerns about whether the current price levels are sustainable over the next 12 months.